Table 1.
Age at diagnosis, disease duration, and sex distribution per autoantibody
| Antibodies | Age at diagnosis Mean (SD); median [IQR] |
Disease duration Mean months (SD); median [IQR] |
Sex Male:female |
|---|---|---|---|
| Amphiphysin | 63 (8.7); 66.0 [55.0–69.0] | 0.39 (1.50); 0 [0–0] | 8:15 |
| GAD | 52.9 (15.5); 55.0 [44.0–63.0] | 21.95 (48.54); 0 [0–24] | 67:145 |
| GlyR | 45.4 (19.2); 49 [37.0–58.0] | 0.81 (3.17); 0 [0–0.2] | 32:25 |
| mGluR1 | 43.6 (15.6); 49.5 [33.0–50.5] | 3.18 (5.65); 1.5 [1.5–1.5] | 7:12 |
| Anna2/Ri | 63.5 (8.9); 63.5 [58.0–70.0] | 1.38 (4.52); 0 [0–0] | 9:31 |
| Yo/PCA-1 | 59.1 (16.2); 62.0 [51.0–71.0] | 5.77 (9.71); 2 [0–6] | 4:15 |
| Anti-Caspr2 | 57.2 (14.5); 60.0 [53.0–66.0] | 3.05 (6.33); 0 [0–2.3] | 18:3 |
| NMDAR | 17.6 (14.4); 15.0 [7.0–24.0] | 0.88 (5.51); 0 [0–0.2] | 66:183 |
| LGI-1 | 62.0 (14.5); 64.0 [57.0–72.0] | 3.45 (6.21); 1.5 [0.5–4] | 33:11 |
| CRMP5/CV2 | 62.9 (11.3); 65 [52.0–71.0] | 1.13 (4.80); 0 [0–0] | 12:13 |
| Anna-1/Hu | 44.2 (31.1); 60.0 [9.0–67.0] | 6.55 (14.48); 0 [0–1] | 5:12 |
| IgLON5 | 62.4 (6.5); 62.5 [58.0–67.0] | 16.79 (37.91); 0 (0–2) | 9:17 |
| DPPX | 48.2 (15.9); 50.5 [38.0–59.5] | 1.18 (4.08); 0 [0–0] | 11:5 |
GAD glutamic acid decarboxylase, GlyR glycine receptor, mGluR1 mGluR1 anti-metabotropic glutamate receptor 1, ANNA-2/Ri anti-neuronal nuclear autoantibody type 2, Yo/PCA-1 Purkinje cell cytoplasmic antibody type 1, Caspr2 contactin-associated protein-like 2, NMDAR Anti-N-methyl-D-aspartate receptor, LGI-1 leucine-rich glioma-inactivated 1, CRMP5/CV2 collapsing response-mediator protein-5, ANNA-1/Hu anti-neuronal nuclear autoantibody type 2, IgLON5 immunoglobulin-like cell adhesion molecule 5, DPPX dipeptidyl-peptidase–like protein 6, SD standard deviation, IQR interquartile range